Displaying 1 - 20 of 46 results
Released Company Title Industry Topic
07 Nov 2019
15:30 CET
VIVORYON Vivoryon Therapeutics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Biotechnology Other subject
04 Nov 2019
07:00 CET
VIVORYON Vivoryon Therapeutics to Attend and Present at Investor Conferences in November 2019 Biotechnology Other subject
24 Oct 2019
09:02 CEST
VIVORYON Vivoryon Therapeutics AG: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE WOULD BE UNLAWFUL. Biotechnology Commercial operations
08 Oct 2019
13:37 CEST
VIVORYON Vivoryon Therapeutics AG: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE WOULD BE UNLAWFUL. Biotechnology Takeover bids
29 Aug 2019
07:00 CEST
VIVORYON Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update Biotechnology Commercial results
22 Aug 2019
07:00 CEST
VIVORYON Vivoryon Therapeutics AG to Publish its Half Year 2019 Results on August 29, 2019 Biotechnology Other subject
22 Aug 2019
07:00 CEST
VIVORYON Vivoryon Therapeutics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] Biotechnology Other subject
08 Jul 2019
22:01 CEST
VIVORYON Vivoryon Therapeutics AG: MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology Biotechnology Alliances and agreements
27 Jun 2019
07:00 CEST
VIVORYON Vivoryon Therapeutics AG: Vivoryon Therapeutics AG enters myeloid immune checkpoint drug discovery, and collaborates with the University of Kiel to select cancer therapy candidates from its QPCTL inhibitor portfolio Biotechnology Alliances and agreements
18 Jun 2019
07:00 CEST
VIVORYON Vivoryon Therapeutics AG: Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology Biotechnology Alliances and agreements
12 Jun 2019
07:00 CEST
VIVORYON Probiodrug AG becomes Vivoryon Therapeutics AG Biotechnology Change in Capital
29 May 2019
18:00 CEST
VIVORYON Probiodrug AG: Ordinary General Meeting of Shareholders of Probiodrug AG Biotechnology General meeting / Board Meeting
22 May 2019
07:00 CEST
VIVORYON Probiodrug to attend International Conferences in June 2019 Biotechnology Other subject
16 May 2019
07:00 CEST
VIVORYON Probiodrug AG: Probiodrug Reports First Quarter 2019 Business Update Biotechnology Commercial results
09 May 2019
07:00 CEST
VIVORYON Probiodrug AG: Probiodrug AG to Publish its First Quarter 2019 Business Update on May 16, 2019 Biotechnology Other subject
18 Apr 2019
15:06 CEST
VIVORYON Probiodrug AG: Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 29 May 2019 Biotechnology General meeting / Board Meeting
15 Apr 2019
07:00 CEST
VIVORYON Probiodrug AG: Probiodrug raises EUR 8.2 million in successful private placement of new shares Biotechnology Change in Capital
09 Apr 2019
18:09 CEST
VIVORYON Probiodrug AG: Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares Biotechnology Change in Capital
04 Apr 2019
07:00 CEST
VIVORYON Probiodrug AG: Probiodrug AG has mandated ODDO SEYDLER BANK AG as Designated Sponsor Biotechnology Other subject
28 Mar 2019
07:00 CET
VIVORYON Probiodrug AG: Probiodrug reports full year 2018 financial results Biotechnology Commercial results